We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aptamer Group Extends Collaboration With AstraZeneca To Explore Next-Generation Drug Delivery Approaches
Product News

Aptamer Group Extends Collaboration With AstraZeneca To Explore Next-Generation Drug Delivery Approaches

Aptamer Group Extends Collaboration With AstraZeneca To Explore Next-Generation Drug Delivery Approaches
Product News

Aptamer Group Extends Collaboration With AstraZeneca To Explore Next-Generation Drug Delivery Approaches

Credit: Arek Socha/ Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Aptamer Group Extends Collaboration With AstraZeneca To Explore Next-Generation Drug Delivery Approaches"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aptamer Group, the developer of Optimer™ reagents and therapeutics, has announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company.

This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.   

Optimers are optimized aptamer reagents. Based on oligonucleotide molecules Optimers can bind specifically to a target molecule to act as an antibody alternative. Their ability to fold into distinct secondary or tertiary structures gives them high affinity and specific binding toward cell-specific targets. They are emerging as promising alternatives in a range of applications.

This extension will further unite Aptamer Group’s expertise and knowledge in the development of aptamer-based technologies with AstraZeneca’s leadership in Cardiovascular, Renal and Metabolism (CVRM) therapy development.

Arron Tolley, CEO of Aptamer Group said “We are really pleased to continue the collaboration with AstraZeneca. We believe that our platform technology could be transformational in the development of drug delivery vehicles. Through working with AstraZeneca, we can explore the potential of these new modalities in the early-stage drug development process”.

Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca said “Oligonucleotide conjugates offer the potential to reach a specific cell or tissue, and have the potential to have a real impact for new drug targets identified in renal disease. By working together with Aptamer Group and leveraging their Optimer-based strategies we aim to identify novel targeting aptamers to deliver drug molecules to the kidney.” 

Advertisement